



**Technology:** Etanercept is a recombinant tumor necrosis factor receptor (“TNFR”):F<sub>c</sub> fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.

**Etanercept Claims Challenged in IPR and Litigation\***



\*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

**Etanercept Timeline**



	<i>Sandoz v. Amgen</i> 3:13-cv-02904 (N.D. Cal.) Dismissed for lack of subject matter jurisdiction; Fed. Cir. 14-1693 Affirmed	<i>Amgen v. Sandoz</i> 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulation of infringement	<i>Amgen v. Samsung Bioepis</i> 2:19-cv-11755 (D.N.J.) Ongoing	<i>Coalition for Affordable Drugs v. Amgen</i> IPR2015-01792 Institution denied	<i>Coherus v. Hoffman-La Roche</i> IPR2017-01916 Institution denied	<i>Coherus v. Hoffman-La Roche</i> IPR2017-02066 Institution denied
7,915,225		X	X			
8,063,182	X	X	X			X
8,119,605		X	X			
8,163,522	X	X	X	X	X	
8,722,631		X	X			